Sinopharm Group Statistics

Total Valuation

Sinopharm Group has a market cap or net worth of EUR 6.32 billion. The enterprise value is 14.75 billion.

Market Cap	6.32B
Enterprise Value	14.75B

Important Dates

The next estimated earnings date is Friday, April 25, 2025.

Earnings Date	Apr 25, 2025
Ex-Dividend Date	Jun 16, 2025

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	1.34B

Valuation Ratios

The trailing PE ratio is 6.77.

PE Ratio	6.77
Forward PE	n/a
PS Ratio	0.08
PB Ratio	0.38
P/TBV Ratio	0.68
P/FCF Ratio	5.26
P/OCF Ratio	4.14
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 5.15, with an EV/FCF ratio of 12.27.

EV / Earnings	15.81
EV / Sales	0.21
EV / EBITDA	5.15
EV / EBIT	6.43
EV / FCF	12.27

Financial Position

The company has a current ratio of 1.39, with a Debt / Equity ratio of 0.60.

Current Ratio	1.39
Quick Ratio	1.02
Debt / Equity	0.60
Debt / EBITDA	3.39
Debt / FCF	8.41
Interest Coverage	6.54

Financial Efficiency

Return on equity (ROE) is 8.44% and return on invested capital (ROIC) is 5.61%.

Return on Equity (ROE)	8.44%
Return on Assets (ROA)	2.87%
Return on Invested Capital (ROIC)	5.61%
Return on Capital Employed (ROCE)	12.51%
Revenue Per Employee	714,756
Profits Per Employee	8,621
Employee Count	108,217
Asset Turnover	1.51
Inventory Turnover	8.83

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -20.78% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-20.78%
50-Day Moving Average	2.24
200-Day Moving Average	2.32
Relative Strength Index (RSI)	37.12
Average Volume (20 Days)	2,379

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Sinopharm Group had revenue of EUR 77.35 billion and earned 932.89 million in profits. Earnings per share was 0.30.

Revenue	77.35B
Gross Profit	5.86B
Operating Income	2.36B
Pretax Income	1.85B
Net Income	932.89M
EBITDA	2.67B
EBIT	2.36B
Earnings Per Share (EPS)	0.30

Full Income Statement

Balance Sheet

The company has 7.19 billion in cash and 10.11 billion in debt, giving a net cash position of -2.92 billion.

Cash & Cash Equivalents	7.19B
Total Debt	10.11B
Net Cash	-2.92B
Net Cash Per Share	n/a
Equity (Book Value)	16.76B
Book Value Per Share	3.35
Working Capital	12.85B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 1.53 billion and capital expenditures -325.63 million, giving a free cash flow of 1.20 billion.

Operating Cash Flow	1.53B
Capital Expenditures	-325.63M
Free Cash Flow	1.20B
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 7.57%, with operating and profit margins of 3.05% and 1.21%.

Gross Margin	7.57%
Operating Margin	3.05%
Pretax Margin	2.40%
Profit Margin	1.21%
EBITDA Margin	3.45%
EBIT Margin	3.05%
FCF Margin	1.55%

Dividends & Yields

This stock pays an annual dividend of 0.11, which amounts to a dividend yield of 5.84%.

Dividend Per Share	0.11
Dividend Yield	5.84%
Dividend Growth (YoY)	8.60%
Years of Dividend Growth	4
Payout Ratio	n/a
Buyback Yield	n/a
Shareholder Yield	5.84%
Earnings Yield	14.76%
FCF Yield	19.03%

Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Sinopharm Group has an Altman Z-Score of 2.26. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.26
Piotroski F-Score	n/a